- Home
- AMTB vs ARVN Comparison
AMTB vs ARVN Comparison
Compare AMTB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMTB | ARVN |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.0M | 781.0M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AMTB | ARVN |
|---|---|---|
| Price | $21.05 | $13.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 21 |
| Target Price | ★ $23.75 | $15.71 |
| AVG Volume (30 Days) | 203.4K | ★ 749.6K |
| Earning Date | 04-23-2026 | 05-27-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | ★ 386.36 | 58.84 |
| EPS | ★ 1.26 | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $8.81 | N/A |
| Revenue Next Year | $7.78 | N/A |
| P/E Ratio | $16.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.62 | $5.90 |
| 52 Week High | $23.55 | $14.22 |
Technical Indicators
Market Signals| Indicator | AMTB | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 61.46 |
| Support Level | $19.42 | $11.07 |
| Resistance Level | $23.02 | $13.97 |
| Average True Range (ATR) | 0.78 | 0.79 |
| MACD | -0.16 | 0.12 |
| Stochastic Oscillator | 30.85 | 96.31 |
Price Performance
Historical ComparisonAbout AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.